RTOG-0617

Terminated

Return to Protocol Table

A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer

Principal Investigator

Jeffrey Bradley, MD

Status

Terminated

Date Opened To Accrual

November 27, 2007

Date Closed To Accrual

November 22, 2011

Date of Study Termination

May 20, 2022


Disease Site

Lung [LU] Non-small Cell Lung Cancer

Phase

III

Developmental Therapeutics

No

Primary Objective

To compare the overall survival of patients treated with high-dose versus standard-dose conformal radiation therapy in the setting of concurrent chemotherapy; To compare the overall survival of patients treated with cetuximab versus without cetuximab in the setting of concurrent chemotherapy.

NOTE: See broadcast regarding paclitaxel shortage and RTOG 0617 recommended modifications (broadcast on 9/23/11 and posted to web site on 10/26/11).

 

Patient Population

Newly diagnosed unresectable Stage III A or B non-small cell lung cancer (NSCLC); patients who present with N2 or N3 disease and an undetectable NSCLC primary tumor also are eligible; patients with supraclavicular or contralateral hilar adenopathy are ineligible.

Target Accrual

500

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.